ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2024
Reshaping its Board of Directors at the upcoming Shareholders’ meeting with the aim of enhancing U.S. outreach Preparations for PORTICO-2 Phase III trial with vafidemstat in agitation/aggression in Borderline Personality Disorder ongoing Final data …